The blockbuster drugs Ozempic and Wegovy may help people cut back on drinking, new research published Wednesday in JAMA ...

Researchers believe discovery will springboard research to make more tolerable, effective weight loss treatments accessible ...

Following an impressive data drop this summer highlighting the potential for Eli Lilly’s tirzepatide to stave off progression ...

Some GLP-1 receptor agonists may hold promise as treatments for alcohol use disorder (AUD), a Swedish observational study ...

Stopping semaglutide, marketed as Wegovy and Ozempic, which helps people lose weight , can have severe health impacts, a new ...

Scientists at the University of Copenhagen have discovered a new weight loss drug target that reduces appetite, increases energy expenditure, and improves insulin sensitivity without causing nausea or ...

Semaglutide and liraglutide are associated with reduced AUD and SUD-related hospitalization risks, unlike other GLP-1 ...

The discovery could lead to a new treatment for millions of people with obesity and type 2 diabetes who do not respond well to current treatments.

the GLP-1 pathway affects the gastrointestinal [GI] system and the brain by suppressing appetite for weight loss and reducing ...

Despite crowding in the next-gen weight loss space, Metsera has raised over $500 million since its April launch, indicating a ...

Ro details dietary choices that may help Wegovy's capacity to regulate appetite and foster a healthier weight as well as ...